Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690558 | 0.86 | NR1H4 (0.53) | MAPTNPSR1HCRTR1HCRTR2NR1H4 | |
| SCHEMBL3620853 | 0.86 | NR1H4 (0.56) | MAPTNPSR1NR1I2PKMNR1H4 | |
| SCHEMBL320173 | 0.84 | CYP2C19 (0.50) | MAPTHTTPPARACYP2C19 | |
| SCHEMBL2977001 | 0.84 | MAPT (0.48) | MAPTNPSR1HCRTR1HCRTR2NR1H4 | |
| SCHEMBL9187252 | 0.84 | NR1H4 (0.52) | MAPTNPSR1HCRTR1HCRTR2NR1H4 | |
| SCHEMBL2788529 | 0.84 | ALDH1A1 (0.48) | MAPTNPSR1NR1I2HCRTR1HCRTR2 | |
| Zinc Ion SCHEMBL9187244 | 0.84 | MAPT (0.48) | MAPTNPSR1NR1I2HCRTR1HCRTR2 | |
| SCHEMBL2989587 | 0.84 | MAPT (0.56) | MAPTNPSR1NR1I2HCRTR1HCRTR2 | |
| SCHEMBL1415205 | 0.81 | SCN8A (0.43) | MAPTNPSR1HTTSMN1; SMN2PPARA | |
| SCHEMBL15829329 | 0.81 | MAPT (0.49) | MAPTNPSR1HCRTR1HCRTR2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051278-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2015-06-09 | — | — | US | disclosed |
| EP-2256106-B1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | ASTEX THERAPEUTICS LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8779147-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8404718-B2 | Combinations of pyrazole kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-20120213791-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2012-08-23 | — | — | US | disclosed |
| US-8080666-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2011-12-20 | — | — | US | disclosed |
| US-20110002879-A1 | Combinations of Pyrazole Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| US-20110003799-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2011-01-06 | — | — | US | disclosed |
| EP-2256106-A1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | Astex Therapeutics Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ASTEX THERAPEUTICS LIMITED (UK) | 2008-07-03 | — | — | US | disclosed |
| US-7385059-B2 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7385059-B2 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077419-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| US-4245099-A | ANTIINFLAMMATORY, ANALGESIC, DIURETIC, ANTIPYRETIC AND HYPOTENSIVE AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ROS1, CDK9, GRK4 | MAPT 3385/4885NPSR1 2165/4885NR1I2 447/4885 |
| US-20120213791-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | CDK3, CDK1, CDKL3 | MAPT 482/4885NPSR1 4429/4885NR1I2 819/4885 |
| US-20110002879-A1 | Combinations of Pyrazole Kinase Inhibitors | ERBB4, GRK4, ROS1 | MAPT 3280/4885NPSR1 2300/4885NR1I2 269/4885 |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | CDK1, CDK3, CDK13 | MAPT 2110/4885NPSR1 2700/4885NR1I2 273/4885 |
| US-20110003799-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | CDK1, CDK3, CDK13 | MAPT 2110/4885NPSR1 2700/4885NR1I2 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.